A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

Conditions: Melanoma; Prostate Cancer; Ovarian Cancer; Renal Cell Carcinoma; Colorectal Carcinoma; Pancreatic Carcinoma; Non-small Cell Lung Carcinoma; Solid Tumors; Breast Cancer
Interventions: Drug: Pegilodecakin; Drug: Paclitaxel or Docetaxel and Carboplatin or Cisplatin; Drug: FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil); Drug: gemcitabine/nab-paclitaxel; Drug: Capecitabine; Drug: Pazopanib; Drug: Pembrolizumab; Drug: Paclitaxel; Drug: nivolumab; Drug: Gemcitabine/carboplatin
Sponsors: Eli Lilly and Company; ARMO BioSciences
Active, not **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 25, 2024Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments